DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that Jeffrey Bacha, president & CEO of the Company, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference being held September 10-12, 2017, at the Lotte New York Palace Hotel in New York City.

Mr. Bacha is scheduled to present on Monday, September 11^th at 12:05 PM EDT in the Holmes I Room. The 25-minute presentation will update on corporate events including the Company’s pivotal STAR-3 clinical trial in refractory GBM, ongoing biomarker-driven phase 2 clinical trials in MGMT-unmethylated GBM and plans for expansion of clinical research into additional solid tumors.
A link to a live webcast of Mr. Bacha’s presentation will be available at DelMar Pharmaceutical’s website at www.delmarpharma.com.  A webcast replay will be available approximately two hours after the end of the presentation and will be accessible for one month.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. is developing cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company’s product lead candidate, VAL-083, is a “first-in-class,” small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including glioblastoma multiforme (GBM), ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). VAL-083 has been granted an orphan drug designation by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant glioma.
For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Media Contact:  Fisctank PR (646) 699-1148
Connect with the DelMar Pharmaceuticals on Twitter, LinkedIn, Facebook, and Google+.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.
 
Click here to connect with DelMar Pharmaceuticals (NASDAQ:DMPI) to receive an Investor Presentation.